Earlier quoted context omitted.
The technology really works and is generating results at a rapid pace. This will absolutely not be the next Theranos, although you may be right that there are issues of burnrate and maybe even mismanagement. To me the fact that they have a patent monopoly on "putting DNA through a protein pore with voltage sensing" is tragic. Who knows were we would be today if these patents had been granted to the public domain.
Let's assume the company statements are true, they are shipping on time; what is the break even point for shipping $1,000 starter kits, flow cells, and sample prep items? How many devices are they shipping? What's their revenue? https://www.investopedia.com/terms/b/breakevenanalysis.asp Are they anywhere near break even or are they going to require another large infusion of venture capital and can Nanopore find these…
Their valuation is not about short term sales. Their technology really is somewhat of a holy grail. There is no "simpler" way to read DNA in terms of technology. Everything else involves complicated biochemistry. Illumina beats Nanopore Technologies right now because of the scale of their machines. But they can't scale them down much further without losing performance. The most efficient Illumina machines will always be cupboards or bigger.
No competitor can come up with something better than ONT. Nothing smaller, for certain. The only way to beat Oxford Nanopore in the future will be to implement a very similar nanopore sequencing scheme.